Superworth

Perspective Therapeutics price to book ratio CATX

Market value divided by the book value of the company's net assets, since 2011.

Today, Nov 2, 2026
0.4×
10-year median
2.3×
Against its 10-year history
0th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.4× to 38.3×
Peer median
1.5×

Perspective Therapeutics' price to book ratio is 0.4× as of Nov 2, 2026.

That is below its ten-year median of 2.3×, lower than on 100% of days in the last ten years.

Over that time it ranged from 0.4× in Nov 2026 to 38.3× in Jan 2021.

The median for 10 large drugmakers of a similar size is 1.5×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far0.4×0.4×2.5×
20250.9×0.5×1.4×
20240.7×0.6×14.1×
20231.1×0.5×3.4×
20220.6×0.5×1.0×
20210.8×0.8×38.3×
20207.7×4.4×10.1×
20195.9×2.2×6.4×
20181.9×1.9×6.9×
20172.4×2.1×3.0×
20162.1×1.7×3.4×
20152.6×2.6×4.7×
20143.6×2.6×19.4×
20132.6×2.4×4.4×
20123.2×1.7×7.0×
20113.5×3.5×3.7×

Against its peers

Companies in Drug Manufacturers - General nearest Perspective Therapeutics' size, closest first, today.

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Perspective Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.